Alzheimer's Association International Conference (AAIC)

Phase 1b study results were presented at AAIC 2021, supporting the need for accelerated clinical development of ACI-24 in Alzheimer disease related to DS.

The assistant professor at Cleveland Clinic discussed key factors to consider when choosing repurposed drugs that could show max potential in treating Alzheimer disease.

The ICARE AD-US trial is expected to enroll 6000 participants, with at least 16% of the population aimed at including those from underrepresented communities. The unrelated confirmatory phase 4 trial is still in the process of being designed.

Clive Ballard, MD, professor of age related diseases at University of Exeter, commented on the potential impact that the approval of pimavanserin would have for patients if approved for dementia-related psychosis.

The effect of methylphenidate on Alzheimer disease apathy was observed at 2 months and was sustained throughout the 6 months of the study.

Participants will be enrolled for 18 months, with baseline data provided and compared to the lecanemab phase 2 study cohort.

The duo from the Critical Path Institute discussed how CPAD is revolutionizing data collection within the Alzheimer disease community and the advantages it brings to clinicians.

Clive Ballard, MD, spoke on safety data presented at this year’s AAIC meeting, as well as the impact of symptoms associated with DRP, which can be distressing for individuals and their families.

The therapy, already FDA-approved for individuals with pulmonary artery disease, was significantly associated with reduced likelihood of Alzheimer disease in both the 65-74 year range and those older than 75 years.

Ballard, a professor of age related diseases at University of Exeter, discussed the results from a recent trial of pimavanserin in dementia-related psychosis, and data presented at this year’s AAIC meeting.

Findings presented at AAIC 2021 found that long-term, daily treatment with non-invasive stimulation was both safe and well-tolerated in patients with Alzheimer disease.

Pooled data from the phase 3 clinical development of aducanumab (Aduhelm; Biogen) suggest that ARIA remains a mostly asymptomatic problem, with MRI providing an effective way to monitor events.

The agent, which is FDA-approved for hyperlipidemia, showed significant improvements in plasma glucose, lipid levels, and trends in cardiovascular imaging biomarkers.

Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic detailed the state of Alzheimer disease and what research particularly grabbed his attention at AAIC 2020.

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed the role that increased APOE ε4 expression can have on future research and clinical care.

Katrina Celis, MD, a postdoctoral fellow at the University of Miami Miller School of Medicine, discussed how ancestral genetics can play a key role in Alzheimer disease risk.

The investigators wrote that the Alzheimer’s Association “Part the Cloud” funded 24-week treatment trial is now warranted after sargramostim showed a safe and tolerable profile.

Data from 2 posters presented at AAIC 2020 suggest that there is an unmet need for safe and effective treatments for patients who experience dementia-related psychosis.

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center detailed the phase 2 study findings of nilotinib in patients with Alzheimer disease.

Excessive alcohol intake, head injury, and air pollution are among the newest dementia risk factors added to the Lancet Commission report.

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.

Results presented virtually at AAIC 2020 support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.

Compared to treatment with lisinopril, those treated with the angiotensin receptor blocker candesartan showed improvements on the Trial Making Test part A and B and Hopkins Verbal Learning Test-Revised delayed recall.

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.

A trio of studies presented at AAIC 2020 suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.